122 related articles for article (PubMed ID: 19139731)
1. Outcomes after auto-SCT in African Americans with multiple myeloma.
Khaled Y; Abidi MH; Janakiraman N; Kato K; Levine JE; Reddy P; Medina M; Peres E; Hanbali A; Mineishi S
Bone Marrow Transplant; 2009 Jun; 43(11):845-51. PubMed ID: 19139731
[TBL] [Abstract][Full Text] [Related]
2. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
3. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Bone Marrow Transplant; 2015 Feb; 50(2):204-8. PubMed ID: 25347006
[TBL] [Abstract][Full Text] [Related]
4. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
[TBL] [Abstract][Full Text] [Related]
5. Impact of early relapse after auto-SCT for multiple myeloma.
Kumar S; Mahmood ST; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Sep; 42(6):413-20. PubMed ID: 18587435
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
7. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
Olin RL; Vogl DT; Porter DL; Luger SM; Schuster SJ; Tsai DE; Siegel DL; Cook RJ; Mangan PA; Cunningham K; Stadtmauer EA
Bone Marrow Transplant; 2009 Mar; 43(5):417-22. PubMed ID: 18850013
[TBL] [Abstract][Full Text] [Related]
8. Second auto-SCT for treatment of relapsed multiple myeloma.
Gonsalves WI; Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2013 Apr; 48(4):568-73. PubMed ID: 23000647
[TBL] [Abstract][Full Text] [Related]
9. Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.
Yhim HY; Kim K; Kim JS; Kang HJ; Kim JA; Min CK; Bae SH; Park E; Yang DH; Suh C; Kim MK; Mun YC; Eom HS; Shin HJ; Yoon HJ; Kwon JH; Lee JH; Kim YS; Yoon SS; Kwak JY
Bone Marrow Transplant; 2013 Mar; 48(3):425-32. PubMed ID: 22941384
[TBL] [Abstract][Full Text] [Related]
10. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver MJ; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
Br J Haematol; 2001 Sep; 114(4):822-9. PubMed ID: 11564069
[TBL] [Abstract][Full Text] [Related]
11. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.
Luoma S; Silvennoinen R; Rauhala A; Niittyvuopio R; Martelin E; Lindström V; Heiskanen J; Volin L; Ruutu T; Nihtinen A
Ann Hematol; 2021 Jun; 100(6):1553-1567. PubMed ID: 33866396
[TBL] [Abstract][Full Text] [Related]
13. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
14. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
[TBL] [Abstract][Full Text] [Related]
15. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
19. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
20. Durable remission with salvage second autotransplants in patients with multiple myeloma.
Shah N; Ahmed F; Bashir Q; Qureshi S; Dinh Y; Rondon G; Wen S; Thall P; Khan H; Giralt S; Champlin R; Qazilbash MH
Cancer; 2012 Jul; 118(14):3549-55. PubMed ID: 22086552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]